Nucleai

In recognition of Breast Cancer Awareness Month, we’re highlighting some of our recent case studies and presentations focused on advancing biomarker discovery and patient stratification in breast cancer.

Targeted therapies like antibody-drug conjugates (ADCs) hold great promise, but identifying which patients will truly benefit remains a key challenge.

💡 Explore our latest resources:
🔹 AI-aided HER2 Ultralow Scoring to Enable Accurate Patient Stratification for ADCs
https://hubs.li/Q03QGs0R0

🔹 AI-augmented Scoring of the Bystander Effect for Effective ADC Patient Selection
https://hubs.li/Q03QGrRH0

🔹 Unleashing the Power of Computational Pathology – Pathology Visions 2025 Poster Presentation
https://hubs.li/Q03QGrXl0

🎗️ These studies, alongside other ongoing work at Nucleai, help drive a deeper understanding of breast cancer biology and support more informed treatment decisions.

Wishing everyone celebrating a Shanah Tovah — a sweet and meaningful New Year. Thank you to our team, partners, and clients for your continued trust and support. 🍎🍯
שנה טובה ומתוקה!